Pharsight

Arymo Er patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9549899 ZYLA Abuse deterrent pharmaceutical compositions for controlled release
Jul, 2033

(9 years from now)

US9044402 ZYLA Abuse-deterrent pharmaceutical compositions for controlled release
Jul, 2033

(9 years from now)

Arymo Er is owned by Zyla.

Arymo Er contains Morphine Sulfate.

Arymo Er has a total of 2 drug patents out of which 0 drug patents have expired.

Arymo Er was authorised for market use on 09 January, 2017.

Arymo Er is available in tablet, extended release;oral dosage forms.

Arymo Er can be used as management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

The generics of Arymo Er are possible to be released after 01 July, 2033.

Drugs and Companies using MORPHINE SULFATE ingredient

Market Authorisation Date: 09 January, 2017

Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of ARYMO ER before it's drug patent expiration?
More Information on Dosage

ARYMO ER family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic